Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04088032
Title Neoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast Cancer
Recruitment Withdrawn
Gender female
Phase Phase I
Variant Requirements No
Sponsors Alison Stopeck
Indications

Her2-receptor negative breast cancer

Therapies

Abemaciclib + Durvalumab + Exemestane

Abemaciclib + Anastrozole + Durvalumab

Abemaciclib + Durvalumab + Letrozole

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.